NK Cell Multiple Myeloma is under clinical development by HK inno.N and currently in Phase II for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase II drugs for Multiple Myeloma (Kahler Disease) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NK Cell Multiple Myeloma’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NK Cell Multiple Myeloma overview

Cell therapy is under development for the treatment of multiple myeloma. The therapeutic candidate comprises of natural killer (NK) cells.

HK inno.N overview

HK inno.N, formerly CJ HealthCare, a subsidiary of Kolmar Korea Co Ltd, is a manufacturer of active pharmaceutical ingredients, OTC drugs, and pharmaceutical medicines. Its finished product portfolio includes EPOKINE for the treatment of renal anemia, LEUKOKINE to treat neutropenia, CALMTOP for the treatment of colorectal cancer, MOVELOXIN, and CINEZOLID, OMAPONE a parenteral nutrition product, and PEMTA an infusion solution. HK inno.N provides OTC drugs such as CJ condition, hongsamjin gold, hutgaesoo, mach max, roboca poli, sankle eye drops and solar vita. The company has production facilities in Icheon, Osong and Daeso; Korea. HK inno.N is headquartered in Seoul, South Korea.

For a complete picture of NK Cell Multiple Myeloma’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.